+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets



Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets



Jak-Stat 1(4): 292-299



STAT transcription factors are regulators of critical cellular processes such as proliferation, survival, and self-renewal. While the activity of these proteins is tightly regulated under physiological conditions, they can become constitutively activated in a broad range of human cancers. This inappropriate STAT activation leads to enhanced transcription of genes that can directly lead to the malignant phenotype. Since STATs are largely dispensable for normal cell function, this has raised the possibility that STATs might be key targets for cancer therapy. Although a number of structure-based strategies have been used to develop STAT inhibitors, an alternate approach is to use cell-based assays that make use of the transcriptional function of STATs. Employing these systems, one can screen large chemical libraries to identify compounds that specifically block the function of a given STAT. This approach can lead to the identification of compounds that inhibit STATs by a variety of mechanisms, and can suggest novel targets for therapy. This type of functional screening strategy has already identified a drug that potently inhibits STAT3, and which is now being evaluated in a clinical trial for patients with chronic lymphocytic leukemia.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670429

Download citation: RISBibTeXText

PMID: 24058786

DOI: 10.4161/jkst.22662


Related references

Strategies for generating less toxic P-selectin inhibitors: pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits. Journal of Molecular Graphics & Modelling 27(4): 546-557, 2008

Comparative screening and validation as a novel tool to identify STAT-specific inhibitors. European Journal of Pharmacology 740: 417-420, 2015

Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β-lactamase. Theoretical Biology & Medical Modelling 10: 22-22, 2013

Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 beta-lactamase. 2013

Homology modeling and virtual screening approaches to identify potent inhibitors of slingshot phosphatase 1. Journal of Molecular Graphics & Modelling 39: 65-70, 2013

Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors. Bio Systems 138: 39-52, 2016

Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits. Bioorganic & Medicinal Chemistry 16(7): 4138-4149, 2008

A stereotaxic technique in man allowing multiple spatial and temporal approaches to intracranial targets. Journal of Neurosurgery 17: 708-720, 1960

Recent Hits Acquired by BLAST (ReHAB): a tool to identify new hits in sequence similarity searches. Bmc Bioinformatics 6: 23-23, 2005

A survey on the computational approaches to identify drug targets in the postgenomic era. Biomed Research International 2015: 239654-239654, 2016

Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits. Bioorganic & Medicinal Chemistry 20(9): 2930-2939, 2012

In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation. Chemmedchem 4(3): 440-444, 2009

Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxidants & Redox Signaling 11(10): 2535-2552, 2009

Molecular approaches to identify novel targets for future development of antifungal agents. Journal of Medical and Veterinary Mycology 32 Suppl 1: 287-298, 1994

Molecular approaches to identify in vivo expressed genes as drug targets. Medicinal Chemistry Research 12(4-5): 175, 2003